NO20012995L - Forbindelser nyttige for behandling av inflammatoriske sykdommer - Google Patents

Forbindelser nyttige for behandling av inflammatoriske sykdommer

Info

Publication number
NO20012995L
NO20012995L NO20012995A NO20012995A NO20012995L NO 20012995 L NO20012995 L NO 20012995L NO 20012995 A NO20012995 A NO 20012995A NO 20012995 A NO20012995 A NO 20012995A NO 20012995 L NO20012995 L NO 20012995L
Authority
NO
Norway
Prior art keywords
treatment
inflammatory diseases
compounds useful
compounds
useful
Prior art date
Application number
NO20012995A
Other languages
English (en)
Other versions
NO20012995D0 (no
Inventor
Duncan Robert Armour
David Brown
Miles Stuart Congreve
Paul Martin Gore
Darren Victor Steven Green
Stuart Holman
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20012995D0 publication Critical patent/NO20012995D0/no
Publication of NO20012995L publication Critical patent/NO20012995L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20012995A 1998-12-18 2001-06-15 Forbindelser nyttige for behandling av inflammatoriske sykdommer NO20012995L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds
PCT/EP1999/010000 WO2000037444A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
NO20012995D0 NO20012995D0 (no) 2001-06-15
NO20012995L true NO20012995L (no) 2001-08-15

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012995A NO20012995L (no) 1998-12-18 2001-06-15 Forbindelser nyttige for behandling av inflammatoriske sykdommer

Country Status (26)

Country Link
US (1) US6867192B1 (no)
EP (1) EP1140837B1 (no)
JP (1) JP4431282B2 (no)
KR (1) KR20010101258A (no)
CN (1) CN1330637A (no)
AR (1) AR023727A1 (no)
AT (1) ATE273954T1 (no)
AU (1) AU760169B2 (no)
BR (1) BR9916282A (no)
CA (1) CA2355630A1 (no)
CO (1) CO5170533A1 (no)
CZ (1) CZ20012209A3 (no)
DE (1) DE69919580T2 (no)
ES (1) ES2226488T3 (no)
GB (1) GB9828074D0 (no)
GT (1) GT199900217A (no)
HK (1) HK1038744A1 (no)
HU (1) HUP0104867A3 (no)
IL (1) IL142908A0 (no)
NO (1) NO20012995L (no)
NZ (1) NZ511478A (no)
PE (1) PE20001387A1 (no)
PL (1) PL348059A1 (no)
TR (1) TR200101709T2 (no)
WO (1) WO2000037444A1 (no)
ZA (1) ZA200103948B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
JP2006528988A (ja) 2003-05-20 2006-12-28 ジェネンテック・インコーポレーテッド アルファ−４インテグリンのチオカルバメート阻害剤
CA2566979A1 (en) 2004-06-04 2005-12-15 Genentech, Inc. Use of a cd20 antibody in treatment of multiple sclerosis
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN104916258B (zh) 2010-02-02 2018-02-16 追踪有限公司 用于控制显示装置的电路
CN102834763B (zh) 2010-02-02 2015-07-22 皮克斯特罗尼克斯公司 用于制造填充冷密封流体的显示装置的方法
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
EP3148518B1 (en) * 2014-05-30 2022-11-30 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
PL3319639T3 (pl) * 2015-07-08 2021-03-08 Axerovision, Inc. Kompozycje farmaceutyczne zawierające antagonistę integryny alfa4 do stosowania w leczeniu stanów zapalnych oka
EP3359572A2 (en) 2015-10-06 2018-08-15 H. Hoffnabb-La Roche Ag Method for treating multiple sclerosis
EP4067368A1 (en) * 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112021007213A2 (pt) 2018-10-30 2021-08-10 Gilead Sciences, Inc. derivados de quinolina como inibidores de integrina alfa4beta7
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2021363705A1 (en) * 2020-10-21 2023-06-15 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) * 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
JP2002501537A (ja) 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのスルホンアミド類
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
JP2002501518A (ja) 1997-05-30 2002-01-15 セルテック セラピューティックス リミテッド 抗炎症性チロシン誘導体

Also Published As

Publication number Publication date
ZA200103948B (en) 2002-11-15
US6867192B1 (en) 2005-03-15
CA2355630A1 (en) 2000-06-29
CN1330637A (zh) 2002-01-09
IL142908A0 (en) 2002-04-21
CZ20012209A3 (cs) 2001-09-12
ATE273954T1 (de) 2004-09-15
WO2000037444A1 (en) 2000-06-29
NZ511478A (en) 2003-08-29
CO5170533A1 (es) 2002-06-27
ES2226488T3 (es) 2005-03-16
JP2002533326A (ja) 2002-10-08
AR023727A1 (es) 2002-09-04
DE69919580T2 (de) 2005-09-01
EP1140837A1 (en) 2001-10-10
HK1038744A1 (zh) 2002-03-28
HUP0104867A2 (hu) 2002-04-29
PL348059A1 (en) 2002-05-06
TR200101709T2 (tr) 2001-12-21
GB9828074D0 (en) 1999-02-17
GT199900217A (es) 2001-06-09
HUP0104867A3 (en) 2002-06-28
NO20012995D0 (no) 2001-06-15
JP4431282B2 (ja) 2010-03-10
EP1140837B1 (en) 2004-08-18
DE69919580D1 (de) 2004-09-23
KR20010101258A (ko) 2001-11-14
AU760169B2 (en) 2003-05-08
PE20001387A1 (es) 2000-12-22
AU3039100A (en) 2000-07-12
BR9916282A (pt) 2001-10-02

Similar Documents

Publication Publication Date Title
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20031443D0 (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
NO20021474D0 (no) Forbindelser for behandling av ischemi
NO20010882L (no) Terapier for behandling av lungesykdommer
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20024005L (no) Pteridinforbindelser for behandling av psoriasis
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
ID26102A (id) Proses pembuatan senyawa-senyawa stilbena
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
ID26097A (id) Proses pembuatan pakaian luar sekali pakai
NO20024058D0 (no) Fremgangsmåte for fremstilling av et oksazolyletanolderivat
NO20003454L (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO20005479L (no) sPLA2-hemmende forbindelser til behandling av sykdom
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20033290L (no) Pyrrolderivater for behandling av cytokinformidlede sykdommer
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20012811D0 (no) Fremgangsmåte for fremstilling av p-klorfenyl-propanol- derivat
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO996166L (no) FremgangsmÕte for behandling av avluter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application